Send to

Choose Destination
J Clin Psychopharmacol. 2020 Jan/Feb;40(1):14-17. doi: 10.1097/JCP.0000000000001158.

Lower Prolactin Levels in Patients Treated With Aripiprazole Regardless of Antipsychotic Monopharmacy or Polypharmacy.

Author information

From the Department of Psychiatry, Graduate School of Medical and Dental Sciences, Niigata University, Niigata.
Japanese Society of Clinical Neuropsychopharmacology.
Japan Psychiatric Hospital Association, Tokyo.
Department of Psychiatry, School of Medicine, Dokkyo Medical University, Mibu.
Department of Psychiatry, Shiga University of Medical Science, Otsu.
Department of Health and Nutrition, Faculty of Health and Nutrition, Yamagata Prefectural Yonezawa University of Nutrition Sciences, Yonezawa, Japan.



Hyperprolactinemia is a troublesome adverse effect of antipsychotics. Aripiprazole (ARP), which is one of second-generation antipsychotics, has been reported to lower serum prolactin (PRL) levels. However, few studies have compared the effect of ARP on plasma PRL levels between monopharmacy and polypharmacy with antipsychotics.


We conducted a large-scale investigation of the physical risk for inpatients with schizophrenia using a questionnaire covering demographic data, the number, dose and type of antipsychotics, and serum PRL levels.


Sufficient data to conduct an assessment of the effect on PRL levels between antipsychotic monopharmacy and polypharmacy were obtained from 316 of the inpatients. Serum PRL levels in ARP combination group were lower than non-ARP combination group, regardless of antipsychotic monopharmacy or polypharmacy.


The present study suggests that ARP lowers serum PRL levels regardless of monopharamacy or polypharmacy with antipsychotics.

Supplemental Content

Full text links

Icon for Wolters Kluwer
Loading ...
Support Center